Priority review drugs approved by the <scp>FDA</scp> and the <scp>EMA</scp>: time for international regulatory harmonization of pharmaceuticals?

Abstract

Significant differences exist in the characteristics of the priority review drugs approved by the FDA and the EMA. Harmonization of the US and European regulatory frameworks may facilitate timely approval of pharmaceutical products.